<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639638</url>
  </required_header>
  <id_info>
    <org_study_id>CONDI 02 AR</org_study_id>
    <nct_id>NCT01639638</nct_id>
  </id_info>
  <brief_title>Recurrent and Nonrecurrent Condyloma Treatment</brief_title>
  <official_title>Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Elea Phoenix S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorio Elea Phoenix S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment is considered successful if the difference in the response in the reduction of the&#xD;
      affected area is above 30% for any of the doses compared to placebo Patients will be&#xD;
      randomised to 1 of 3 treatment arms&#xD;
&#xD;
        1. Placebo&#xD;
&#xD;
        2. CIGB-300 - 5 mg&#xD;
&#xD;
        3. CIGB-300 - 15 mg&#xD;
&#xD;
      A two week screening visit will take place to assess patient eligibility, at least 2 to 5&#xD;
      target lesions (area of the lesion between 20 to 80 mm2), should be identified. Patients&#xD;
      included in the study will be randomly assigned to one of three study arms. Treatment&#xD;
      consists of 3 perilesional applications at the base of the target lesion every 48 hours with&#xD;
      a window of ±24hs.&#xD;
&#xD;
      After each application the potential local and systemic adverse events will be identified and&#xD;
      monitored.&#xD;
&#xD;
      After the last application is made, weekly clinical evaluations for 3 weeks and then every&#xD;
      two weeks, until week 12 will take place. At this time, clinical assessment of efficacy will&#xD;
      be carried out that will define the response to treatment.&#xD;
&#xD;
      After this visit, patients will be followed every 3 months until one year after the last&#xD;
      treatment has been completed to confirm response and long-term security of the CIGB-300&#xD;
      application.&#xD;
&#xD;
      At screening, at 2 and 8 weeks as well as at 6 and 12 months post-treatment blood studies&#xD;
      will be conducted to assess the safety from the systemic point of view.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with complete response of target lesion in each study group</measure>
    <time_frame>Up to one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events during the application of the study drug</measure>
    <time_frame>Up to one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the perilesional application of CIGB300 in the reduction in the number and area of genital warts lesions treated directly</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional effect of CIGB300 by assessing the area and number of genital warts lesions not directly treated</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of CIGB300 to avoid recurrence of the lesions</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal dose, in comparison with placebo</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Recurrent Condyloma</condition>
  <condition>Nonrecurrent Condyloma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CIGB-300 - 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CIGB-300 - 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROAPOPTOTIC PEPTIDE CIGB 300</intervention_name>
    <description>CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.</description>
    <arm_group_label>CIGB-300 - 15 mg</arm_group_label>
    <arm_group_label>CIGB-300 - 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent signed by the patient&#xD;
&#xD;
          2. Women with clinical diagnosis of recurrent and non recurrent genital condyloma&#xD;
&#xD;
          3. Presence of a condylomatous lesion or area of external confluent condylomatous lesions&#xD;
             of not less than 20 or more than 80 mm2&#xD;
&#xD;
          4. The number of warts should be between 2 and 20&#xD;
&#xD;
          5. External genital warts or in perigenital regions&#xD;
&#xD;
          6. Negative pregnancy test&#xD;
&#xD;
          7. Age between 18 and 65 years inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having received surgery treatment, ablative or immunomodulator treatment during the 30&#xD;
             days prior to inclusion&#xD;
&#xD;
          2. Presence of genital warts only located in the cervix, vagina, bladder or rectum&#xD;
&#xD;
          3. Pregnancy and lactation&#xD;
&#xD;
          4. Patients of childbearing age who are not using an adequate contraception method during&#xD;
             treatment to prevent pregnancy.&#xD;
&#xD;
          5. Inadequately controlled chronic diseases (hypertension, diabetes, chronic kidney&#xD;
             failure, heart failure, hyperthyroidism, malignant neoplasms, epilepsy, severe mental&#xD;
             depression)&#xD;
&#xD;
          6. Patients with previous diagnosis of bleeding disorders and other chronic blood&#xD;
             disorders (von Willebrand disease, haemophilia, leukaemia) or use of anticoagulants&#xD;
             within 30 days before the study&#xD;
&#xD;
          7. Current genital herpes, which requires application of topical antivirals&#xD;
&#xD;
          8. Immunosuppressive disease, current intake of immunosuppressive/ immunomodulatory drugs&#xD;
             within 30 days before the study.&#xD;
&#xD;
          9. Autoimmune Diseases (Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis,&#xD;
             Diabetes)&#xD;
&#xD;
         10. Severe allergy history as urticaria, dermatitis or persistent bronchitis and bronchial&#xD;
             asthma&#xD;
&#xD;
         11. Febrile illness (temperature greater than 38ºC) at the time or within 24 hours prior&#xD;
             to administration of the product or suspected acute infectious disease by clinical&#xD;
             examination&#xD;
&#xD;
         12. Diseases that compromise the patient's consciousness or the ability to give informed&#xD;
             consent or to collaborate in the study&#xD;
&#xD;
         13. Concomitant skin lesions that prevent the administration of condylomatous lesions at&#xD;
             the proposed site&#xD;
&#xD;
         14. Participating in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratorio Elea SACIFyA</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1417AZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.elea.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent and non-recurrent genital condyloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

